Shares of Aerie Pharmaceuticals Inc. (NASDAQ:AERI) saw an uptick in trading volume on Wednesday . 371,314 shares were traded during trading, a decline of 5% from the previous session’s volume of 392,883 shares.The stock last traded at $20.12 and had previously closed at $19.73.

A number of brokerages have recently issued reports on AERI. Zacks Investment Research cut Aerie Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, May 4th. Canaccord Genuity restated a “buy” rating on shares of Aerie Pharmaceuticals in a report on Tuesday, May 3rd. Brean Capital reiterated a “buy” rating on shares of Aerie Pharmaceuticals in a research note on Tuesday, May 3rd. Cantor Fitzgerald started coverage on Aerie Pharmaceuticals in a research note on Thursday, June 2nd. They issued a “buy” rating and a $44.00 price target for the company. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $45.00 price target on shares of Aerie Pharmaceuticals in a research note on Tuesday. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. The stock has a consensus rating of “Buy” and an average price target of $42.50.

The firm has a 50 day moving average of $18.11 and a 200-day moving average of $16.17. The firm’s market capitalization is $525.49 million.

Aerie Pharmaceuticals (NASDAQ:AERI) last posted its quarterly earnings data on Wednesday, August 3rd. The company reported ($0.72) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.74) by $0.02. On average, equities analysts anticipate that Aerie Pharmaceuticals Inc. will post ($2.74) EPS for the current fiscal year.

In related news, major shareholder Foresite Capital Fund Ii, L.P. purchased 250,000 shares of the firm’s stock in a transaction dated Friday, July 22nd. The stock was bought at an average price of $17.50 per share, for a total transaction of $4,375,000.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Aerie Pharmaceuticals, Inc is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company’s primary product candidates are Rhopressa and Roclatan.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.